Price T Rowe Associates Inc Liquidia Corp Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Liquidia Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 18,357 shares of LQDA stock, worth $179,898. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,357
Previous 14,341
28.0%
Holding current value
$179,898
Previous $212,000
4.25%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding LQDA
# of Institutions
157Shares Held
35.9MCall Options Held
1.79MPut Options Held
380K-
Patient Square Capital LP Menlo Park, CA7.18MShares$70.4 Million40.01% of portfolio
-
Black Rock Inc. New York, NY4.24MShares$41.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.4MShares$33.3 Million0.0% of portfolio
-
Findell Capital Management LLC New York, NY2.4MShares$23.5 Million13.89% of portfolio
-
State Street Corp Boston, MA2.23MShares$21.9 Million0.0% of portfolio
About Liquidia Corp
- Ticker LQDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,362,300
- Market Cap $631M
- Description
- Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...